Full Name
Mark Caulfield
Job title
Vice Principal for Health for Queen Mary’s Faculty of Medicine and Dentistry
Affiliation
Barts Lifesciences and Queen Mary University of London
Speaker bio
Professor Sir Mark Caulfield is Vice Principal for Health, Professor of Clinical Pharmacology at Queen Mary University of London and the CEO of Barts Life Sciences, a research and innovation partnership between Queen Mary University of London and Barts Health NHS Trust.
Professor Caulfield graduated in Medicine in 1984 from the London Hospital Medical College and trained in Clinical Pharmacology at St Bartholomew’s Hospital where he developed a research programme in molecular genetics of hypertension and translational clinical research.
At Queen Mary University of London Professor Caulfield has made substantial contributions to the discovery of genes related to blood pressure, cardiovascular health, cancer and rare diseases. His research has changed national and international guidance for high blood pressure. He was Director of Queen Mary’s William Harvey Research Institute between 2002-2020 and was elected to the Academy of Medical Sciences in 2008.
Professor Caulfield was appointed Chief Scientist for Genomics England in 2013, charged with delivery of the 100,000 Genomes Project on whole genome sequencing in rare disease, cancer and infection. At Genomics England, he was instrumental in delivering the 100,000 Genomes Project which has delivered life-changing results for many patients. He has also worked with NHS England to co-create the National Genomic Test Directory, which offers equitable access for 56 million people to appropriate genomic tests. Professor Caulfield was awarded a knighthood in 2019 for his leadership of the 100,000 Genomes Project.
In July 2021, Professor Caulfield stepped down from his role as Chief Scientist for Genomics England and is taking a major leadership in Barts Life Sciences a partnership between Queen Mary University of London and Barts Health NHS Trust. This is driving the development of a world-leading life sciences campus at Whitechapel focusing on digital precision healthcare. He is a member of the Barts Health NHS trust Board and is the President Elect of the British Pharmacological Society.
Professor Caulfield graduated in Medicine in 1984 from the London Hospital Medical College and trained in Clinical Pharmacology at St Bartholomew’s Hospital where he developed a research programme in molecular genetics of hypertension and translational clinical research.
At Queen Mary University of London Professor Caulfield has made substantial contributions to the discovery of genes related to blood pressure, cardiovascular health, cancer and rare diseases. His research has changed national and international guidance for high blood pressure. He was Director of Queen Mary’s William Harvey Research Institute between 2002-2020 and was elected to the Academy of Medical Sciences in 2008.
Professor Caulfield was appointed Chief Scientist for Genomics England in 2013, charged with delivery of the 100,000 Genomes Project on whole genome sequencing in rare disease, cancer and infection. At Genomics England, he was instrumental in delivering the 100,000 Genomes Project which has delivered life-changing results for many patients. He has also worked with NHS England to co-create the National Genomic Test Directory, which offers equitable access for 56 million people to appropriate genomic tests. Professor Caulfield was awarded a knighthood in 2019 for his leadership of the 100,000 Genomes Project.
In July 2021, Professor Caulfield stepped down from his role as Chief Scientist for Genomics England and is taking a major leadership in Barts Life Sciences a partnership between Queen Mary University of London and Barts Health NHS Trust. This is driving the development of a world-leading life sciences campus at Whitechapel focusing on digital precision healthcare. He is a member of the Barts Health NHS trust Board and is the President Elect of the British Pharmacological Society.
Speaking At
